RxSight Q4 revenue $28.6M (+78% YoY); LAL volume +98% YoY; guides FY2024 rev $128-135M

RxSight, Inc.

2023-FY EPS reported -$1.41 revenue$89,077,000

Q4 2023 revenue $28.6M, up 78% YoY, with 77 LDDs sold and 18,071 LALs (+98% YoY).
Full year 2023 revenue $89.1M (+82% YoY); net loss $(48.6)M vs $(66.8)M in 2022.
Q4 gross margin 62% vs 46% YoY; full year gross margin 60% vs 44%.
FY2024 guidance: revenue $128M-$135M (44-52% growth); gross margin 65-67%; opex $125M-$128M.
Cash and investments $127.2M at Dec 31; Q4 adjusted net loss $(4.8)M or $(0.13)/share.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RxSight, Inc. updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).

Period: the three and twelve months ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 28, 2024, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-022053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.